We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Purpose
This guidance aims to assist sponsors of active medical devices for therapy with a diagnostic function with meeting their obligations and outlines transitional arrangements to help comply with new regulations.
From 25 November 2021 active medical devices for therapy with a diagnostic function will be required to meet regulatory requirements demonstrating the safety and performance for Class III medical devices.
Background
In early 2019 the Therapeutic Goods Administration (TGA) conducted a public consultation seeking feedback on a proposal to reclassify active medical devices for therapy with a diagnostic function that significantly determines patient management. The proposed regulatory changes supported the commitment made in the Australian Government Response to the Review of Medicines and Medical Devices Regulation to align Australian medical device regulations, where possible and appropriate, with the European Union framework.
Stakeholders who responded to the public consultation were broadly supportive of the proposed changes and the Therapeutic Goods Legislation Amendment (2019 Measures No.1) Regulations 2019 was made on 12 December 2019.
The amendments include the reclassification of active medical devices for therapy with a diagnostic function that determines the patient management from Class IIa (low-medium risk)/Class IIb (medium- high risk) to Class III (high risk), effective from 25 November 2021.
Requirements for reclassification
The requirements include:
- more detailed assessment of the manufacturer’s quality management systems and assessment of technical documentation related to each device
- conformity assessment documents demonstrating procedures appropriate for a Class III device
- mandatory audit assessment by the TGA for device inclusion applications, including assessment of clinical evidence.